Answers are grounded in this paper and cite their sources.
Genomic analysis reveals 52 biosynthetic gene clusters in marine Aspergillus sydowii MNP-2, indicating substantial potential for therapeutic natural product discovery.
Genome mining strategy plays a key role in the discovery of bioactive secondary metabolites (SMs) from microorganisms. This work highlighted deciphering the biosynthetic potential of an Arctic marine-derived strain Aspergillus sydowii MNP-2 by a combination of whole genome analysis and antiSMASH as well as feature-based molecular networking (MN) in the Global Natural Products Social Molecular Networking (GNPS). A completed genomic assembly of 34.9 Mb containing 10 contigs with an N50 scaffold size of 4.1 Mb was generated and a total of 13,218 protein-coding genes and 46 rRNA, 7 sRNA, 32 snRNA and 119 rRNA were annotated using Nr, GO, COG, Pfam, KEGG and other databases. AntiSMASH results indicated that strain MNP-2 harbors 52 biosynthetic gene clusters (BGCs), suggesting a great potential for producing SMs with various structure motifs. Noticeably, these BGC-encoded SMs with therapeutic potential were detected in its metabolic products through GNPS and MN analyses.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: